- Home
- CIGI vs RYTM Comparison
CIGI vs RYTM Comparison
Compare CIGI & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGI
- RYTM
- Stock Information
- Founded
- CIGI 1972
- RYTM 2008
- Country
- CIGI Canada
- RYTM United States
- Employees
- CIGI N/A
- RYTM N/A
- Industry
- CIGI
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- CIGI
- RYTM Health Care
- Exchange
- CIGI Nasdaq
- RYTM Nasdaq
- Market Cap
- CIGI 7.7B
- RYTM 6.4B
- IPO Year
- CIGI N/A
- RYTM 2017
- Fundamental
- Price
- CIGI $152.93
- RYTM $101.03
- Analyst Decision
- CIGI Buy
- RYTM Strong Buy
- Analyst Count
- CIGI 7
- RYTM 13
- Target Price
- CIGI $174.33
- RYTM $109.77
- AVG Volume (30 Days)
- CIGI 113.1K
- RYTM 605.0K
- Earning Date
- CIGI 11-04-2025
- RYTM 11-04-2025
- Dividend Yield
- CIGI 0.20%
- RYTM N/A
- EPS Growth
- CIGI N/A
- RYTM N/A
- EPS
- CIGI 2.21
- RYTM N/A
- Revenue
- CIGI $5,169,495,000.00
- RYTM $156,287,000.00
- Revenue This Year
- CIGI $16.18
- RYTM $46.14
- Revenue Next Year
- CIGI $7.46
- RYTM $63.37
- P/E Ratio
- CIGI $67.85
- RYTM N/A
- Revenue Growth
- CIGI 16.63
- RYTM 53.55
- 52 Week Low
- CIGI $100.86
- RYTM $45.91
- 52 Week High
- CIGI $170.65
- RYTM $106.52
- Technical
- Relative Strength Index (RSI)
- CIGI 39.94
- RYTM 56.10
- Support Level
- CIGI $149.80
- RYTM $97.97
- Resistance Level
- CIGI $154.09
- RYTM $102.92
- Average True Range (ATR)
- CIGI 3.19
- RYTM 3.22
- MACD
- CIGI -0.73
- RYTM 0.10
- Stochastic Oscillator
- CIGI 24.96
- RYTM 73.45
About CIGI Colliers International Group Inc. Subordinate Voting Shares
Colliers International Group Inc provides commercial real estate professional services and investment management to corporate and institutional clients across different countries around the world. Its operating segments are; Real Estate Services, Engineering, Investment Management, and Corporate. Maximum revenue for the company is generated from its Real Estate Services segment, which offers services like transaction and debt finance services, outsourcing in property management, valuation and advisory, loan servicing, property sales brokerage, and lease brokerage services, among others. Geographically, the company generates maximum revenue from the United States and the rest from Canada, Australia, the United Kingdom, Poland, China, India, and other regions.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.